Myelomas
A Modular Phase I/II, Open-Label, Multiple Centre Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0305 as Monotherapy or in Combination With Anticancer Agent(s) in Participants with Relapsed or Refractory Multiple Myeloma (D7230C0001)
- Details
ClinicalTrials.gov ID:
NCT06106945
Diagnosis Type:
NA
USOR Number:
- Address
,
P: